{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115932","form_type":"8-K","ticker":"SENS","cik":"0001616543","company_name":"Senseonics Holdings, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.413680+00:00","generated_at":"2026-06-22T03:42:26.056836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senseonics Q3 revenue $4.6M (+31% YoY); net loss $60.4M on non-cash fair value adjustments","bullets":["Revenue $4.6M vs $3.5M a year ago; U.S. revenue $1.9M (up from $0.6M), OUS $2.7M.","Net loss of $60.4M ($0.13/share) compared to net income of $42.9M ($0.10/share) in Q3 2021 due to non-cash items.","Gross profit improved to $0.8M from negative $1.2M in the prior-year period.","FY 2022 revenue guidance narrowed to $15-17M from prior $14-18M range.","Completed enrollment of pivotal 365-day sensor trial; Eversense E3 launched globally with Ascensia."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115932","json":"https://secwatch.observer/filing/0001104659-22-115932.json","markdown":"https://secwatch.observer/filing/0001104659-22-115932.md","text":"https://secwatch.observer/filing/0001104659-22-115932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616543/000110465922115932/0001104659-22-115932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616543/000110465922115932/tm2229974d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:42:26.056836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50e4b318bd08f9f7666a2b108b10c808318fd014","claim":"Senseonics Holdings, Inc. reported the quarter ended September 30, 2022 results: revenue $4.6 million, net income $60.4 million, or ($0.13) per share, EPS ($0.13) per share. Guidance lowered.","evidence_excerpt":"sensor. ● Received positive coverage decisions from Blue Cross Blue Shield of Florida and others, adding 5 million covered lives for Eversense E3 CGM. ● Generated revenue of $4.6 million in the third quarter of 2022. “Having launched the partnership with the Nurse Practitioner Group to expand access with in-home and in-office insertion options, we continue to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1616543/000110465922115932/0001104659-22-115932-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$4.6 million"},{"label":"Net income","value":"$60.4 million, or ($0.13) per share"},{"label":"EPS","value":"($0.13) per share"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}